Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solithromycin PK and safety in pediatric bacterial infection
NCT02268279Phase 1Completed
- Sponsor
- Melinta Therapeutics
- Start
- Jan 2015
- Primary completion
- Oct 2016
- Modality
- RNA-Targeting Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of solithromycin in bacterial infection, sponsored by Melinta Therapeutics. Primary endpoint: Area under the plasma concentration versus time curve. Started Jan 2015; status: completed.
02
Drugs
solithromycin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02268279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268279.